Comparative Pharmacology
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus ULTRATAG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus ULTRATAG.
MPI DMSA KIDNEY REAGENT vs ULTRATAG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
Inhibits hepatic glucose production by activating AMP-activated protein kinase (AMPK) and reduces intestinal glucose absorption; also improves insulin sensitivity.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
NOT FOUND
None Documented
None Documented
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Terminal elimination half-life is 12-15 hours (mean 13.5 h); clinically significant for twice-daily dosing in hepatic impairment or drug interactions.
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Primarily renal excretion of unchanged drug (60-70%); biliary excretion accounts for 20-25%; fecal elimination <10%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical